Notably, NSCLC patients receiving standard EGFR-tyrosine kinase inhibitors (TKIs) treatment showed downregulated EGFR-induced PD-L1 expression and upregulated IFN-γ-induced PD-L1 expression. The gene discussed is IFNG; the disease is non-small cell lung carcinoma.